ORAL N-ACETYLCYSTEINE FOR MENSTRUAL PAIN IN ADOLESCENTS: A RANDOMIZED CONTROLLED STUDY OF OXIDATIVE STRESS REDUCTION WITHOUT HORMONAL MODULATION.

TL;DR

NAC supplementation (600 mg twice daily during menstruation) reduced menstrual pain intensity, NSAID use, and markers of oxidative stress in adolescents with primary dysmenorrhea compared to placebo . The study was small (50 participants) and limited to three menstrual cycles, leaving questions about long-term safety and real-world effectiveness.

What the Study Found

A randomized, double-blind, placebo-controlled trial of 50 adolescents aged 13-19 years with moderate to severe menstrual pain tested whether NAC, an antioxidant precursor to glutathione, could reduce dysmenorrhea without hormonal or NSAID interventions. The rationale was straightforward: mounting evidence suggests oxidative stress contributes to menstrual pain, creating a mechanistic case for antioxidant intervention in a population where conventional treatment options (NSAIDs or hormonal birth control) may be poorly tolerated or inappropriate.

Participants received either NAC at 600 mg twice daily for five days starting with menstruation, or placebo, for three consecutive cycles. The results favored NAC across multiple measures. Pain intensity on a 0-10 visual analogue scale averaged 4.6 (±1.3) in the NAC group versus 5.9 (±1.1) in placebo, a difference of 1.3 points that reached statistical significance (p<0.001). Rescue ibuprofen use dropped substantially: the NAC group used 666.7 mg per cycle compared to 1,299.7 mg in placebo (p<0.001), with fewer NSAID-use days per cycle as well (1.5 vs. 2.4 days, p=0.004). This matters practically because it reduced medication burden without loss of symptom management.

The biological mechanism was tracked via urinary 8-iso-prostaglandin F2-alpha (8-iso-PGF2-alpha), a validated marker of oxidative stress. NAC significantly reduced this marker compared to placebo (0.6 ±0.2 vs. 0.8 ±0.2 ng/mg creatinine, p=0.010), supporting the oxidative stress hypothesis. Multivariate analysis confirmed treatment assignment independently predicted both pain reduction and oxidative stress reduction, meaning the effect wasn't explained by baseline differences or other measured variables. No adverse events were reported in either group during the three-cycle observation window.

The study's main limitation is scope. With only 50 participants and three menstrual cycles of follow-up, the evidence shows short-term efficacy in a specific population but cannot address long-term safety, sustainability, or whether NAC works comparably to other antioxidants. The authors explicitly call for further research on these points. The modest absolute pain reduction (1.3 points on a 10-point scale) is clinically meaningful for symptom severity but still leaves adolescents in the "mild to moderate" pain range despite treatment.

What This Means for You

If you are an adolescent with moderate to severe dysmenorrhea and NSAIDs or hormonal birth control are poorly tolerated or not preferred, NAC supplementation at 600 mg twice daily during menstruation represents a plausible, evidence-supported option worth discussing with your healthcare provider. The mechanism is intuitive (reducing oxidative stress), and the safety profile in this trial was clean.

However, this is one small trial. Before considering NAC a standard recommendation, additional evidence should establish durability beyond three cycles, compare it directly to established treatments, and test it in larger, more diverse adolescent populations. You should also not expect complete pain elimination: the study showed reduction, not resolution.

If you proceed with NAC, standard dosing in this trial was 600 mg twice daily (1,200 mg/day total) taken for five days starting with menstruation. This is a recognized dosing range in clinical research, though individual tolerability and optimal duration remain open questions. Any supplement should be discussed with your provider before starting, especially if you are on other medications or have underlying health conditions.

Study Details

Sources

PubMed: https://pubmed.ncbi.nlm.nih.gov/42289121/